Extract
We read with interest the paper by Lee et al. [1], reporting on the high rate of nonadherence in a group of severe asthma patients who were potentially suitable for biological therapy or bronchial thermoplasty. In our experience the issue of nonadherence is not confined to patients under active consideration for biological therapy. We have identified significant rates of nonadherence in a group of patients on long-term Omalizumab therapy.
Abstract
Nonadherence with inhaled preventer therapy is prevalent in previously adherent patients on long-term omalizumab http://ow.ly/5wdE30kp0MM
Footnotes
Conflict of interest: D.J. Allen reports non-financial support from Mundipharma for attendance at the ERS meeting, and speaker fees for presenting at an educational meeting sponsored by Astra Zeneca, outside the submitted work.
Conflict of interest: L-J. Holmes reports personal fees for speaking at conferences from Novartis and TEVA, outside the submitted work.
- Received May 31, 2018.
- Accepted June 4, 2018.
- Copyright ©ERS 2018
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
